Is NCT05917145 recruiting in Rochester, MN?

Yes, NCT05917145 is currently recruiting participants at its Rochester, MN location. This glioblastoma clinical trial is actively enrolling qualified participants.

How do I join the glioblastoma clinical trial in Rochester?

To join this clinical trial in Rochester, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Rochester clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Glioblastoma Clinical Trial in Rochester, MN

Who Can Participate

Inclusion Criteria

Age ≥ 18 years

Histological confirmation of one of the following:

Glioblastoma, IDH-wildtype

Grade 3 or 4 IDH1/2 mutant astrocytoma (2021 WHO classification)

Measurable disease as defined in Section 11.0

Disease progression after previous treatment for glioma with radiation and chemotherapy

Minimum life expectancy of at least 3 months

Group C only: Dose Expansion, Brain Tumor Penetration Group: plan for radiosurgery and surgical resection as part of routine clinical care

ECOG Performance Status (PS) 0, 1 or 2 (Appendix I)

The following laboratory values obtained ≤15 days prior to registration:

Hemoglobin ≥9.0 g/dL

Leukocytes ≥3.0 x 109/L

Absolute neutrophil count (ANC) ≥1500/mm3 or 1.5 x 109/L

Platelet count ≥100,000/mm3 or 100 x 109/L

Total bilirubin ≤1.5 x ULN and \<3 mg/dL for patients with Gilbert's disease

Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤3 x ULN

PT/INR/aPTT ≤1.5 x ULN OR if patient is receiving anticoagulant therapy and INR or aPTT is within target range of therapy

Calculated creatinine clearance ≥45 ml/min using the Cockcroft-Gault formula below:

Creatinine clearance for males = (140-age)(weight in kg)(72)(serum creatinine inmgdL⁄)

Creatinine clearance for females = (140-age)(weight in kg)(0.85)(72)(serum creatinine inmgdL⁄)

Negative pregnancy test done ≤7 days prior to registration, for persons of childbearing potential only

Willing to take light-protective measures during the study and for two weeks after their last dose of WSD0628

Provide written informed consent

Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)

Willingness to provide mandatory tissue specimens for correlative research

Exclusion Criteria

Any of the following because this study involves an investigational agent, the genotoxic, mutagenic, and teratogenic effects of which on the developing fetus and newborn are unknown:

Pregnant persons

Nursing persons

Persons of childbearing potential and persons able to father a child who are unwilling to employ adequate contraception

Uncontrolled intercurrent illness including, but not limited to:

ongoing or active infection

symptomatic congestive heart failure

unstable angina pectoris

cardiac arrhythmia

or psychiatric illness/social situations that would limit compliance with study requirements

Any of the following cardiac criteria:

Marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \>480 milliseconds (ms) (CTCAE Grade 1) using Fredericia's QT correction formula.

History of additional risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of Long QT. Syndrome).

Use of concomitant medications that prolong the QT/QTc interval

History of myocardial infarction ≤6 months prior to registration, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias

Known coagulopathy increasing the risk of bleeding or history of clinically significant hemorrhage, including significant intracranial tumor related hemorrhage

Any of the following medications:

Enzyme-inducing anticonvulsants within two weeks of enrollment NOTE: Patients can be enrolled after a change to non-enzyme inducing anticonvulsants)

Patients taking more than 8 mg of dexamethasone per day (or equivalent steroid dose) at time of enrollment

Any of the following prior therapies:

Radiation therapy \<= 26 weeks prior to registration (including gamma tiles)

Chemotherapy, immunotherapy, or any investigational drug \<= four weeks prior to registration,

or carmustine (BCNU) or lomustine (CCNU) \<= six weeks prior to registration

Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease

History of hypersensitivity to active or inactive excipients of WSD0628 or drugs with a similar chemical structure or class to WSD0628

Refractory nausea and vomiting if not controlled by supportive therapy, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of WSD0628

Uncontrolled hypertension

History of severe brain-injury or stroke

Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Rochester?

Yes, this clinical trial (NCT05917145) has an active research site in Rochester, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Glioblastoma Treatment Options in Rochester, MN

If you're searching for glioblastoma treatment options in Rochester, MN, this clinical trial (NCT05917145) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Rochester research site is actively enrolling participants for this clinical trial. You'll receive care from experienced glioblastoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all glioblastoma clinical trials near you to find additional studies recruiting in your area.

Glioblastoma Clinical Trial in Rochester, MN

Expert Care in Rochester

IRB Approved

No-Cost Care

Apply for This Rochester Location

Why Participate?

Simple Process

About This Glioblastoma Study in Rochester